Peptide 19-2.5 Inhibits Heparan Sulfate-Triggered Inflammation in Murine Cardiomyocytes Stimulated with Human Sepsis Serum

Myocardial dysfunction in sepsis has been linked to inflammation caused by pathogen-associated molecular patterns (PAMPs) as well as by host danger-associated molecular patterns (DAMPs). These include soluble heparan sulfate (HS), which triggers the devastating consequences of the pro-inflammatory cascades in severe sepsis and septic shock. Thus, there is increasing interest in the development of anti-infective agents, with effectiveness against both PAMPs and DAMPs. We hypothesized that a synthetic antimicrobial peptide (peptide 19-2.5) inhibits inflammatory response in murine cardiomyocytes (HL-1 cells) stimulated with PAMPs, DAMPs or serum from patients with septic shock by reduction and/or neutralization of soluble HS. In the current study, our data indicate that the treatment with peptide 19-2.5 decreases the inflammatory response in HL-1 cells stimulated with either PAMPs or DAMPs. Furthermore, our work shows that soluble HS in serum from patients with Gram-negative or Gram-positive septic shock induces a strong pro-inflammatory response in HL-1 cells, which can be effectively blocked by peptide 19-2.5. Based on these findings, peptide 19-2.5 is a novel anti-inflammatory agent interacting with both PAMPs and DAMPs, suggesting peptide 19-2.5 may have the potential for further development as a broad-spectrum anti-inflammatory agent in sepsis-induced myocardial inflammation and dysfunction.

[1]  Romain Pirracchio,et al.  Should We Monitor ScVO2 in Critically Ill Patients? , 2011, Cardiology research and practice.

[2]  M. Hornef,et al.  The anti-inflammatory effect of the synthetic antimicrobial peptide 19-2.5 in a murine sepsis model: a prospective randomized study , 2013, Critical Care.

[3]  S. Shaw,et al.  The Emerging Role of TLR and Innate Immunity in Cardiovascular Disease , 2012, Cardiology research and practice.

[4]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. , 2009, Chest.

[5]  C. Natanson,et al.  The coronary circulation in human septic shock. , 1986, Circulation.

[6]  M. Hornef,et al.  New Antiseptic Peptides To Protect against Endotoxin-Mediated Shock , 2010, Antimicrobial Agents and Chemotherapy.

[7]  J. Platt,et al.  Conditional signaling by Toll‐like receptor 4 , 2005, The FASEB Journal.

[8]  C. Parish,et al.  Heparan Sulfate: A Ubiquitous Glycosaminoglycan with Multiple Roles in Immunity , 2013, Front. Immunol..

[9]  I. Vlodavsky,et al.  Heparin, heparan sulfate and heparanase in inflammatory reactions , 2009, Thrombosis and Haemostasis.

[10]  M. Tsan,et al.  Endogenous ligands of Toll‐like receptors , 2004, Journal of leukocyte biology.

[11]  K. Brandenburg,et al.  Antimicrobial peptides and their potential application in inflammation and sepsis , 2012, Critical Care.

[12]  P. Matzinger.  The Danger Model: A Renewed Sense of Self , 2002, Science.

[13]  C. Parish.  The role of heparan sulphate in inflammation , 2006, Nature Reviews Immunology.

[14]  T. Goldmann,et al.  Preclinical Investigations Reveal the Broad-Spectrum Neutralizing Activity of Peptide Pep19-2.5 on Bacterial Pathogenicity Factors , 2013, Antimicrobial Agents and Chemotherapy.

[15]  R. Hancock,et al.  Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies , 2006, Nature Biotechnology.

[16]  M. Sallisalmi,et al.  Vascular adhesion protein‐1 and syndecan‐1 in septic shock , 2012, Acta anaesthesiologica Scandinavica.

[17]  Alexis Peralta,et al.  Toll-like receptors are key participants in innate immune responses. , 2007, Biological research.

[18]  Xiaopei Huang,et al.  Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. , 2012, Blood.

[19]  M. Weigand,et al.  Sepsis-Induced Degradation of Endothelial Glycocalix , 2010, TheScientificWorldJournal.

[20]  T. van der Poll,et al.  Host innate immune responses to sepsis , 2013, Virulence.

[21]  Shau-ku Huang,et al.  Endotoxin contamination contributes to the in vitro cytokine-inducing activity of osteopontin preparations. , 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[22]  I. Nagaoka,et al.  Antimicrobial Cathelicidin Peptide LL-37 Inhibits the LPS/ATP-Induced Pyroptosis of Macrophages by Dual Mechanism , 2014, PloS one.

[23]  J. Hauber,et al.  A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses. , 2012, The Journal of infectious diseases.

[24]  J. Platt,et al.  Receptor-Mediated Monitoring of Tissue Well-Being Via Detection of Soluble Heparan Sulfate by Toll-Like Receptor 41 , 2002, The Journal of Immunology.

[25]  J. Platt,et al.  Cutting Edge: An Endogenous Pathway to Systemic Inflammatory Response Syndrome (SIRS)-Like Reactions through Toll-Like Receptor 41 , 2004, The Journal of Immunology.

[26]  T. Falla,et al.  Antimicrobial peptides: therapeutic potential , 2006, Expert opinion on pharmacotherapy.

[27]  A. Malmström,et al.  TLR4 dependent heparan sulphate-induced pancreatic inflammatory response is IRF3-mediated , 2011, Journal of Translational Medicine.

[28]  Sheldon Weinbaum,et al.  The structure and function of the endothelial glycocalyx layer. , 2007, Annual review of biomedical engineering.

[29]  G. Morelli,et al.  Peptide inhibitors against herpes simplex virus infections , 2013, Journal of peptide science : an official publication of the European Peptide Society.

[30]  Jinghua Chen,et al.  Immunomodulatory activity of heparan sulfate mimetics from Escherichia coli K5 capsular polysaccharide in vitro. , 2015, Carbohydrate polymers.

[31]  G. Horgan,et al.  Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR , 2002 .

[32]  L. MacMillan-Crow,et al.  Role of Mitochondrial Oxidants in an In Vitro Model of Sepsis-Induced Renal Injury , 2012, Journal of Pharmacology and Experimental Therapeutics.

[33]  M. Singer,et al.  Mechanisms of sepsis-induced cardiac dysfunction , 2007, Critical care medicine.

[34]  Roger C. Bone.  Definitions for Sepsis and Organ Failure , 1993 .

[35]  L. Moldawer,et al.  ROLE OF TOLL-LIKE RECEPTORS IN THE DEVELOPMENT OF SEPSIS , 2007, Shock.

[36]  S. Phipps,et al.  Soluble Heparan Sulfate Fragments Generated by Heparanase Trigger the Release of Pro-Inflammatory Cytokines through TLR-4 , 2014, PloS one.

[37]  K. Walley,et al.  Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. , 2006, Cardiovascular research.

[38]  N J Izzo,et al.  HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Campo,et al.  Glycosaminoglycans reduced inflammatory response by modulating toll-like receptor-4 in LPS-stimulated chondrocytes. , 2009, Archives of biochemistry and biophysics.

[40]  B. Funke,et al.  Sepsis and major abdominal surgery lead to flaking of the endothelial glycocalix. , 2011, The Journal of surgical research.

[41]  M. Bodelsson,et al.  Circulating glycosaminoglycan species in septic shock , 2014, Acta anaesthesiologica Scandinavica.

[42]  Jay Steingrub,et al.  International study of the prevalence and outcomes of infection in intensive care units , 2009 .